Evaluation of therapeutic effect of Glycyrrhiza glabra plant in the treatment of patients with Covid 19

Evaluation of therapeutic effect of Glycyrrhiza glabra plant in improving and accelerating the treatment of patients with Covid 19

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220712055444N1

Enrollment

Registered

2022-07-26

Start date

2022-08-23

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient with mild Covid19. Coronavirus infection, unspecified

Interventions

Intervention group: In addition to routine treatment, mild covid patients will receive 300 mg licorice for 7 days.This study is before/after and has no control group.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: The age group is 18 to 60 years old, having no history of specific diseases, not having drug interactions

Exclusion criteria

Exclusion criteria: Having acute corona, having an specific disease such as cardiovascular diseases, having autoimmune diseases, having drug interactions, pregnancy

Design outcomes

Primary

Measure	Time frame
IL6,IL1,CRP,WBC. Timepoint: 7 days. Method of measurement: Elisa kits and Blood cell counting machine.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactalireza ahmadzadeh

Shahid Beheshti University of Medical Sciences

a.ahmadzadeh@sbmu.ac.ir+98 21 2271 8531

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026